Compare Ascendis Pharma A/S (ASND) vs Caterpillar Inc (CAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Caterpillar Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Caterpillar Inc trades at $942.05 (market cap $438.67B). The key difference: Caterpillar Inc is far larger — about 24.7× Ascendis Pharma A/S's market cap, and Caterpillar Inc pays a 0.68% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CAT | |
|---|---|---|
Market Cap | $17.74B | $438.67B |
Sector | Health | Industrials |
52-Week High | $277.18 | $1.06K |
52-Week Low | $163.32 | $404.64 |
Enterprise Value | $18.11B | $477.67B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Caterpillar (CAT) trades at $952.41, up 1.49% with strong year-to-date momentum driven by AI infrastructure demand. The stock shows bullish technical positioning above key support levels, while fundamentals reveal robust profitability with 13.33% net margins and 51.35% ROE. Recent earnings beats and a $10.2B generator segment from data centers highlight growth catalysts, though elevated valuations (P/E 47.43) warrant caution.
Outlook remains positive with analyst consensus targeting $1,010 (6% upside), supported by 32 consecutive dividend increases and AI-driven backlog growth. Key risks include cyclical exposure, debt levels at 43.94% of assets, and geopolitical sensitivity. Institutional sentiment leans bullish with 55% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Caterpillar Inc
Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →
